UNSPSC 51162619: Cyclexanone

This classification denotes an antitussive agent with the molecular formula C16H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 2OU4KS37EO, chemically known as 4(5h)-oxazolone, 2-(cyclopropylamino)-5-phenyl- (9ci) but more generally known as cyclexanone, which bears US NIH Compound Identifier 26701. European Medicines Agency schedules Cyclexanone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06845MIG. The term CYCLEXANONE is an International Non-Proprietary Name.

UNSPSC 51162619 Cyclexanone, a Commodity code, shows minimal alignment with actual state and local procurement activity in the recent opportunity record. The code nominally describes cyclexanone, a chemical solvent, but the two posted opportunities detail procurement of naloxone (an opioid antagonist medication) and generic multi-source pharmaceuticals and over-the-counter products—neither of which is cyclexanone or a chemical solvent. The issuing bodies span different jurisdictional types: Seminole County, Florida (a county health department seeking naloxone and drug deactivation systems) and the Minnesota Multistate Cooperative Purchasing Alliance, administered by the Minnesota Department of Administration (a cooperative purchasing vehicle serving state and local government facilities across multiple states including Oregon). Neither opportunity reflects demand for cyclexanone itself.

The geographic activity recorded under this code centers on Florida and Minnesota, with MMCAP's reach extending across participating states. Seminole County posted an Invitation for Bid (IFB 60459723LAS) on June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. MMCAP issued a Request for Proposal (S1070000015802) on January 20, 2026, with a question cutoff of February 18, 2026, and a proposal due date of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with contract effectiveness targeted for July 1, 2026. The code appears to be mistagged or inactive for its nominal scope; vendors pursuing state and local work should verify actual commodity classification before investing in pursuit strategy.